Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Abstract Text:

    ianko d iankovIanko D Iankov,boris blechaczBoris Blechacz,chunsheng liuChunsheng Liu,jeffrey d schmeckpeperJeffrey D Schmeckpeper,james e tararaJames E Tarara,mark j federspielMark J Federspiel,noel capliceNoel Caplice,stephen j russellStephen J Russell,ianko d iankovIanko D Iankov,boris blechaczBoris Blechacz,chunsheng liuChunsheng Liu,jeffrey d schmeckpeperJeffrey D Schmeckpeper,james e tararaJames E Tarara,mark j federspielMark J Federspiel,noel capliceNoel Caplice,stephen j russellStephen J Russell,

    Attenuated measles viruses (MVs) propagate selectively in human tumor cells, and phase I clinical trials are currently underway to test their oncolytic activity. A major theoretical impediment to systemic MV application is the presence of pre-existing antiviral immunity. We hypothesized that autologous MV-infected cells might be a more reliable vehicle than cell-free virions to deliver the infection to tumor cells in subjects with neutralizing titers of anti-measles antibodies. Our in vitro studies, using a dual-color fluorescent model, demonstrated efficient cell-to-cell transfer of infection via heterofusion. In contrast to infection by naked virions, heterofusion between infected cell carriers and tumor cells was more resistant to antibody neutralization. Infected monocytic, endothelial, or stimulated peripheral blood cells could deliver oncolytic MV to tumor lesions in vivo, after intravenous (i.v.) or intraperitoneal (i.p.) administration. Single or repeated i.p. injections of monocytic carriers significantly improved survival of animals bearing human ovarian cancer xenografts. Systemic or i.p. injection of MV-infected cells successfully transferred infection by heterofusion to Raji lymphomas or hepatocellular carcinoma tumors in the presence of neutralizing antibodies. These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can "bypass" the pre-existing humoral immunity against MV.Molecular Therapy (2007) 15, 114-122. doi:10.1038/sj.mt.6300020.

    Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Publishing Authors By Initials

    id iankovID Iankov,b blechaczB Blechacz,c liuC Liu,jd schmeckpeperJD Schmeckpeper,je tararaJE Tarara,mj federspielMJ Federspiel,n capliceN Caplice,sj russellSJ Russell,id iankovID Iankov,b blechaczB Blechacz,c liuC Liu,jd schmeckpeperJD Schmeckpeper,je tararaJE Tarara,mj federspielMJ Federspiel,n capliceN Caplice,sj russellSJ Russell,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Molecular therapy : the journal of the American So

    VOLUME: 15

    Page Numbers: 114-22

    Journal Abbreviation: Mol. Ther.

    ISSN: 1525-0016

    DAY: 13

    MONTH: Jan

    YEAR: 2007

    Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100890581

    Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

    AFFILIATION: 1Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Mol Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News